biotech-finance
(4)
Kristine Ball Knows What Happens After the Science Gets Interesting
She began in audit, learned biotech from the inside, and became the operator companies call when science must survive contact with money, markets and momentum.
John Craighead’s Second Language Is the Business of Cells
He trained in cell biology, learned to read biotech through markets and corporate strategy, and now leads Syntax Bio as it turns a laboratory insight into a repeatable process.
David Woodhouse Knows What Biotech Must Prove Next
He trained in molecular pharmacology, advised on more than $90 billion in deals, and spent a decade inside one research company. Now Nuvig's CEO is bringing those three languages to the same table.
Elizabeth Czerepak
Elizabeth Czerepak is a life sciences finance executive with more than three decades in big pharma, venture capital, and public biotech. She is Chief Financial Officer and VP of Corporate Development at Mirror Biologics, a clinical-stage immunotherapy company in Wesley Chapel, Florida, where she also served as acting CEO from July 2024 to May 2025. Over her career she has helped raise hundreds of millions of dollars, taken companies public through IPOs and SPAC mergers, and worked on landmark pharma transactions including the search that led to BASF Pharma's sale to Abbott. She sits on the boards of Delcath Systems and TransCode Therapeutics.